Prevents pregnancy. ANDA 206853, held by Aurobindo Pharma. Desogestrel; Ethinyl Estradiol.
As of Nov 16, 2026, ANDA 206853 (Simliya), held by Aurobindo Pharma, was first approved by FDA on Mar 22, 2017, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE SIMLIYA TM (desogestrel and ethinyl estradiol tablets, USP and ethinyl estradiol tablets, USP) are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table II lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 22, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Simliya0.15MG,N/A;0.02MG,0.01MG · tablet;oral-28 | Desogestrel; Ethinyl Estradiol | Rx |
| Aug 1, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 1, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 25, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 9, 2017 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 22, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters